The following recommendations are based on guidelines for STD screening from the Centers for Disease Control and Prevention, United States Preventive Services Task Force, Infectious Disease Society of America, and the California Department of Public Health–STD Control Branch and Los Angeles County (LAC) of Public Health/Division of HIV & STD Programs. In populations for whom no recommendations exist, screening should be based on risk factors, local epidemiology and prevalence of specific STDs in the particular clinical setting. All women diagnosed with chlamydia, gonorrhea, or trichomonas should be retested for repeat infection at 3 months after treatment. Men diagnosed with chlamydia (CT) or gonorrhea (GC) should also be retested at 3 months. Retesting can also be performed opportunistically anytime the patient returns for care in the 1-12 months after treatment. Other factors to consider prior to screening are summarized in the footnotes below.

<table>
<thead>
<tr>
<th>Population</th>
<th>STD Screening Recommendations</th>
<th>Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women &lt; 25 years of age¹ ² ³</td>
<td>CT and GC (vaginal, cervical, or urine) ..........</td>
<td>Annually All women of child bearing age (15-44) at least once, then repeat according to level of risk</td>
<td>Consider screening more frequently for those at increased risk.</td>
</tr>
<tr>
<td></td>
<td>Syphilis...........................</td>
<td>All women up to 64 years of age at least once, repeat according to risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HIV ...................................</td>
<td>All women 15-44 years at least once⁴</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women 25 years of age and older¹ ² ³</td>
<td>No routine screening for CT and GC; Screen according to risk.</td>
<td>All women 15-44 years at least once⁴</td>
<td>Targeted CT/GC screening recommended for women with risk factors. See footnote 4.</td>
</tr>
<tr>
<td></td>
<td>Syphilis...........................</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HIV ...................................</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnant women¹ ³ ⁵</td>
<td>CT and GC (vaginal, cervical, or urine) ..........</td>
<td>First trimester</td>
<td>Repeat screening for CT, GC, HIV, HBsAg in 3 trimester if at increased risk.</td>
</tr>
<tr>
<td></td>
<td>Syphilis...........................</td>
<td>First trimester</td>
<td>Repeat syphilis screening highly recommended in 3rd trimester &amp; delivery, LAC considered a high morbidity area.</td>
</tr>
<tr>
<td></td>
<td>HIV ...................................</td>
<td>First trimester, third trimester &amp; delivery</td>
<td></td>
</tr>
<tr>
<td>HIV-positive women¹ ³ ⁵ ⁶ ⁷ ⁸</td>
<td>CT and GC (vaginal, cervical, or urine) ..........</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CT and GC (rectal) ..................</td>
<td>Annually (if exposed)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GC (pharyngeal) .....................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Syphilis .............................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trichomoniasis ........................</td>
<td>Repeat screening every 3-6 months, if indicated by risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatitis B Surface Antigen (HBsAg)........</td>
<td>First trimester</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatitis C ..........................</td>
<td>First trimester</td>
<td>Reconsidered CT/GC screening especially in 3rd trimester &amp; delivery, LAC considered a high morbidity area.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>First trimester, third trimester &amp; delivery</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterosexual men¹</td>
<td>No routine screening for STDs.</td>
<td></td>
<td>Targeted screening for CT in high risk settings (e.g. corrections) or if risk factors (e.g. CT in past 24 months)</td>
</tr>
<tr>
<td></td>
<td>Screen according to risk.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HIV ...................................</td>
<td>All men 13-64 years of age at least once, then annually if high-risk</td>
<td></td>
</tr>
<tr>
<td>Men who have sex with men (MSM)¹ ³ ⁴</td>
<td>CT and GC (urine)........................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CT and GC (rectal) ..................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GC (pharyngeal) .....................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Syphilis .............................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HIV ...................................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatitis B Surface Antigen (HBsAg)........</td>
<td>At least once</td>
<td></td>
</tr>
<tr>
<td>HIV-positive men¹ ³ ⁴ ⁵ ⁶ ⁷ ⁸</td>
<td>CT and GC (urine)........................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CT and GC (rectal) ..................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GC, (pharyngeal) ....................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Syphilis .............................</td>
<td>Annually</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatitis B Surface Antigen (HBsAg)........</td>
<td>First visit</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatitis C ..........................</td>
<td>First visit</td>
<td>Reconsidered CT/GC screening especially in 3rd trimester &amp; delivery, LAC considered a high morbidity area.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>First visit</td>
<td></td>
</tr>
</tbody>
</table>

CDC. STD Treatment Guidelines. June 5, 2015. (64/RR3).1-137

¹Human papillomavirus (HPV) testing is recommended as part of cervical cancer screening and management of cervical intraepithelial neoplasia. It is not recommended as part of routine STD screening or prior to initiating HPV vaccination. See the American Society for Colposcopy and Cervical Pathology (www.asccp.org) for further guidance.

²Screening for asymptomatic HSV-2 infection should be offered to select populations including those in partnerships or considering partnerships with HSV-2-infected individuals. Counseling should be provided to patients tested for HSV-2. Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies—California Department of Public Health. www.std.ca.gov

³Risk factors for CT or GC: prior CT or GC infection, particularly in past 24 months; more than one sex partner in the past year; suspicion that a recent partner may have had concurrent infection (e.g., anal or oral sex) because of potential underreporting by patients.

⁴In pregnant women with a history of injection drug use or a history of blood transfusion or organ transplantation before 1982, screening for hepatitis C should be conducted. California Guidelines for STD Screening and Treatment in Pregnancy. www.std.ca.gov

⁵Routine hepatitis B vaccination is recommended for all HIV-infected patients and all MSM. Routine hepatitis A vaccination is recommended for all MSM. Prevaccination serologic testing may be considered, however if testing is not feasible in the current setting, routine vaccination should continue.


⁷Data are insufficient to recommend routine anal cancer screening with anal cytology among HIV-positive men and women. Some clinical centers perform anal cytology screening in populations at high-risk for anal cancer. Programmatic considerations such as availability of providers to perform diagnostic anoscopy in the case of abnormal results should be considered prior to initiating anal cancer screening.

⁸Screening for syphilis in women of childbearing age (15-44 years) is recommended at least once, and should be repeated according to individual level of risk.
Sexually transmitted diseases (STDs) including chlamydia (CT) and gonorrhea (GC) are among the most common reportable infections nationwide. If left untreated, STDs can result in serious health consequences including infertility, ectopic pregnancy and chronic pelvic pain in women. STDs can also increase risk of HIV transmission and acquisition. Because many STDs do not have symptoms, screening for asymptomatic infection is a cornerstone of STD prevention.

Performing a sexual risk assessment

A brief risk assessment can guide decisions about what screening tests for STDs are indicated for particular patients. The content of a brief risk assessment should cover the following areas, summarized as “The 5 P’s”:

| Past STDs: | “Have you ever had an STD in the past?” |
| Partners: | “Have you had sex with men, women, or both?” |
| | “In the past six months, how many people have you had sex with?” |
| | “Have any of your sex partners in the past 12 months had sex with other partners while they were still in a sexual relationship with you?” |
| Practices: | Do you have… vaginal sex (penis in vagina)?” |
| | …anal sex (penis in anus/butt)?” |
| | ….oral sex (penis in mouth or mouth on vagina/vulva)?” |
| | “Have you ever used needles to inject/shoot drugs?” |
| Prevention: | “What do you do to prevent STDs and HIV?” |
| | “Tell me about your use of condoms with your recent partner.” |
| Pregnancy plans and HIV prevention: | “How would it be for you if you were to get pregnant now?” |
| | “What are you doing to prevent pregnancy now?” |
| | “What are you doing to prevent HIV infection?” |

Risk factors by population

| Adolescents and young women (age 25 and younger) | Because of high levels of disease in this age group, sexual activity alone represents a significant risk for acquiring CT, GC, and syphilis. |
| Women over age 25 | Risk factors for CT, GC, and syphilis include: |
| | o Prior CT or GC infection, particularly in past 24 months |
| | o Multiple sex partners within the past year |
| | o Suspicion that a recent partner may have had concurrent partners |
| | o New sex partner in the past 3 months |
| | o Exchanging sex for drugs or money within the past year |
| | o African-American women up to age 30 may be at increased risk; annual screening should be offered. |
| | o Other factors identified locally, including prevalence of infection in the community |
| Men who have sex with men | Risk factors that indicate need for more frequent screening for STDs (CT, GC, syphilis, HIV) include: |
| | o Multiple or anonymous partners |
| | o Intravenous drug use |
| | o Sex in conjunction with illicit drug use, including methamphetamine |
| | o Sex partners who engage in these activities |
| Men who have sex with women | CT screening targeted to men in high risk settings including: adolescents clinics, correctional facilities and STD clinics as well as CT/GC screening in men with prior infection (in past 24 months). |